| Course | NU670 PMHNP Neuroscience and Psychopharmacology |
|---|---|
| Unit | Unit 6 |
| Paper type | Dopamine pathway analysis |
| Length | About 1,120 words, 7 pages double-spaced |
| Format | APA 7 student paper |
| School | Purdue University Global |
| Program | MSN |
| Updated | September 2026 |
Free sample paper for NU670 Unit 6
One Receptor Blocked in Four Places: A Dopamine Pathway Analysis of Haloperidol in a 23-Year-Old in a First Episode of Psychosis
[Student Name]
Purdue University Global
NU670: PMHNP Neuroscience and Psychopharmacology
Unit 6 Dopamine Pathway Analysis
[Instructor Name]
[Date]
The patient is composite; doses and values are bracketed. Evidence grades are the author's.
The Patient After Two Weeks
Mr. [K.] is a [23]-year-old community college student admitted with his first episode of psychosis. For [three] months he had believed his classmates were recording him and heard voices commenting on his actions. He was started on haloperidol [2.5] mg daily, increased to [5] mg on day [ten]. At two weeks, the voices are quieter and he is less certain that he is being recorded. He also reports a stiff neck, restlessness that makes him pace, and new breast tenderness; his prolactin is [58] ng/mL. His mother says he still sits alone and speaks little, as he did before admission.
All four of these changes, the partial relief of psychosis, the movement effects, the raised prolactin and the unchanged withdrawal, can be traced to one action of haloperidol, blockade of the dopamine D2 receptor, in four different pathways.
Pathway One: Mesolimbic, and the Relief of Psychosis
The mesolimbic pathway runs from the ventral tegmental area to the ventral striatum and related limbic regions. The classical dopamine hypothesis holds that excess dopamine activity in the striatum drives positive symptoms such as delusions and hallucinations, and that blocking D2 receptors relieves them.
The human evidence for excess striatal dopamine is now substantial. A meta-analysis of [44] imaging studies comparing [618] patients with [606] controls found elevated presynaptic dopamine function in schizophrenia with a large effect size, a Cohen's d of [0.79], while transporter availability did not differ and D2/3 receptor availability was only slightly raised (Howes et al., 2012). In a separate study using acute dopamine depletion, patients with schizophrenia showed greater occupancy of striatal D2 receptors by their own dopamine than controls, in both first-episode drug-naive patients and treated patients in relapse, and higher synaptic dopamine predicted a better response of positive symptoms to treatment (Abi-Dargham et al., 2000).
Link to Mr. [K.]: the quieter voices and weaker conviction are the effect this pathway predicts. Kapur and colleagues measured D2 occupancy with positron emission tomography in [22] first-episode patients on haloperidol and found that the likelihood of clinical response rose significantly once occupancy exceeded about [65] percent (Kapur et al., 2000).
Evidence grade: strong for elevated presynaptic striatal dopamine and for D2 occupancy predicting response. The imaging does not map cleanly onto the anatomical label "mesolimbic," since the measurements cover the striatum as a whole.
Pathway Two: Nigrostriatal, and the Stiffness and Pacing
The nigrostriatal pathway runs from the substantia nigra to the dorsal striatum and is central to the control of movement. Blocking D2 receptors here produces the extrapyramidal effects that Mr. [K.] is experiencing: acute dystonia in his neck and akathisia, the inner restlessness that makes him pace.
The same PET study found that the likelihood of extrapyramidal side effects rose significantly once D2 occupancy exceeded about [78] percent (Kapur et al., 2000). The gap between 65 percent for response and 78 percent for movement effects is the therapeutic window, and his dose increase on day ten may have pushed him through it.
Evidence grade: strong for the link between high striatal D2 occupancy and extrapyramidal effects in humans.
Pathway Three: Tuberoinfundibular, and the Prolactin
The tuberoinfundibular pathway runs from the hypothalamus to the pituitary, where dopamine normally inhibits prolactin release. Blocking D2 receptors on the pituitary removes that brake. Mr. [K.]'s prolactin of [58] ng/mL and breast tenderness follow directly.
In the PET study, the likelihood of hyperprolactinemia rose significantly once occupancy exceeded about [72] percent (Kapur et al., 2000). The pituitary sits outside the blood-brain barrier, which is one reason prolactin can rise at doses that do not yet cause movement effects.
Evidence grade: strong. The dopamine control of prolactin is established physiology, and the occupancy relationship has been measured in humans.
Pathway Four: Mesocortical, and the Withdrawal That Did Not Change
The mesocortical pathway runs from the ventral tegmental area to the prefrontal cortex. Davis and colleagues proposed that schizophrenia involves too little dopamine activity in the prefrontal cortex alongside too much in subcortical regions, and that the prefrontal deficit contributes to negative symptoms such as withdrawal, reduced speech and poor motivation (Davis et al., 1991). If so, blocking D2 receptors could leave these symptoms unchanged or make them worse.
Link to Mr. [K.]: his withdrawal and reduced speech have not improved, which fits the prediction. It is also consistent with simpler explanations: negative symptoms often respond less to antipsychotics in general, sedation or akathisia may make him less sociable, and two weeks is a short time.
Evidence grade: weak to moderate. The idea is supported by imaging and animal work, but direct human evidence that reduced prefrontal dopamine causes negative symptoms, or that D2 blockade worsens them through this pathway, is limited.
Explaining the Pathways to Him
Mr. [K.] asked why a medicine for his voices was making his neck stiff. The pathway map gives a plain answer that does not require any anatomy: the medicine works by blocking one chemical messenger, and that messenger does several jobs in different parts of the brain and body. Where it drives the frightening thoughts, blocking it helps. Where it helps control movement, blocking it too much causes stiffness and restlessness. Where it keeps a hormone in check, blocking it raises that hormone. This explanation was useful to him for two reasons. It made the side effects feel predictable rather than random, and it made the plan to lower the dose sound like a way to keep the benefit while losing some of the cost, rather than a sign that the treatment had failed. His mother, who had worried that he was getting worse, found the same explanation reassuring.
What the Analysis Changes in His Care
Three practical steps follow from the pathway analysis. First, his dose may be above what he needs. Since response is likely above [65] percent occupancy and movement effects above [78] percent, the team could return to [2.5 to 3] mg and treat the akathisia, rather than adding medications to manage side effects of an unnecessarily high dose. Second, his prolactin should be followed, and his sexual and breast symptoms asked about directly, since these are common reasons young men stop antipsychotics. Third, his negative symptoms need their own plan, including psychosocial treatment and support to return to classes, because the pathway most responsible for his relief is not the one that will restore his motivation.
References
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., Gorman, J. M., & Laruelle, M. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences, 97(14), 8104-8109. https://doi.org/10.1073/pnas.97.14.8104
Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991). Dopamine in schizophrenia: A review and reconceptualization. American Journal of Psychiatry, 148(11), 1474-1486. https://doi.org/10.1176/ajp.148.11.1474
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012). The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies. Archives of General Psychiatry, 69(8), 776-786. https://doi.org/10.1001/archgenpsychiatry.2012.169
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry, 157(4), 514-520. https://doi.org/10.1176/appi.ajp.157.4.514
NU670 Unit 6 instructions, in plain terms
For Unit 6 you analyze how a psychotropic drug's action on one neurotransmitter system produces both its benefits and its side effects. Prompts usually ask for the pathways involved, what the drug does in each, the clinical effect that follows, and a grade for the evidence behind each pairing. A patient case is often required so that each effect can be tied to a symptom or side effect. A length of four to five pages is usual. Faculty give credit to analyses that separate measured human findings from inferred mechanisms and that end with practical implications, such as dose or monitoring changes. Diagrams are optional; clear pairing of pathway, effect and evidence is not.
How the NU 670 Unit 6 example is put together
The patient's first two weeks come first: fewer voices, a stiff neck, pacing, breast tenderness with a prolactin of 58 and unchanged withdrawal. Each pathway then has its own section in the same order: anatomy, what D2 blockade does there, the link to Mr. K. and an evidence grade. The mesolimbic section draws on the Howes meta-analysis and the Abi-Dargham depletion study. The nigrostriatal and tuberoinfundibular sections use the Kapur occupancy thresholds, and a highlighted sentence names the therapeutic window. The mesocortical section presents the Davis hypothesis with simpler alternatives. A section on explaining the pathways to the patient follows, and three practical changes close the paper.
Where the points sit in the NU670 Unit 6 rubric
The rubric for a pathway analysis typically covers neuroanatomical accuracy, pharmacological reasoning, evidence appraisal, clinical application and writing quality. Accuracy is scored on the origin and target of each tract and on what dopamine does there. Pharmacological reasoning rewards a clear account of how one receptor action produces different effects in different places. Evidence appraisal earns full points when each pathway's grade reflects the human data available, which differs sharply between prolactin and negative symptoms. Clinical application scores when the analysis leads to a change in dose, monitoring or treatment planning. Writing points depend on consistent structure and accurate citations. Tables or diagrams can help but do not replace the written reasoning that connects them.
Common NU670 Unit 6 mistakes, and how to avoid them
Students often describe the four pathways from a textbook diagram without tying them to the patient in front of them. Another common error is presenting the mesocortical hypothesis as established fact. Some papers state occupancy thresholds as exact cutoffs rather than approximate bands from one study of one drug. Others treat side effects as a reason to add more medications instead of reconsidering the dose. Negative symptoms are often left out of the plan entirely. And explaining pathways only in technical terms misses the chance to show how the same model can help a patient understand why the medicine that helps him also stiffens his neck.
Get an NU670 Unit 6 example written to your instructions
State the drug class your NU670 Unit 6 prompt calls for, if it names one, with the rubric and whatever table layout your section expects. The first analysis is free and comes back in 24-48h to those instructions, with each tract's normal function stated before its blocked one, a single mechanism accounting for benefit and burden, and every row given an evidence grade. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More NU670 papers and MSN samples
- NU670 Unit 1: Trauma and the Hippocampus Post
- NU670 Unit 2: Rumination and the Default Mode Network
- NU670 Unit 3: Stress Physiology and Early Adversity
- NU670 Unit 4: Evidence Table, Inflammation
- NU670 Unit 5: Depression Biotypes Seminar Reflection
- NU670 Unit 7: Drug Class Explainer
- NU670 Unit 8: Neuroplasticity Brief
- NU670 Unit 9: Study Critique
- NU670 Unit 10: Developmental Neuroscience Paper
- NU657 Unit 6: ICU Handoff Comparison Post
- NU656 Unit 6: Ventilator Plan for Moderate ARDS
- NU655 Unit 6: Family Meeting Summary, Perforation
- NU654 Unit 6: Integrated Plan, Endocarditis
NU670 Unit 6 questions, answered
Does the analysis need to cover second-generation antipsychotics?
Not unless the prompt names them. Much of the same tract logic applies to them, but serotonin 2A antagonism and partial agonism change the picture enough to need their own discussion. If your prompt names one class, keep to it; adding a second invites comparisons the rubric may not reward and eats space the tract analysis needs.
How should occupancy figures be presented?
As findings, with their source. The thresholds most often cited come from a PET study in first-episode patients, and they vary between individuals and drugs. Presenting them as approximate bands observed in that study, rather than as targets, keeps the analysis accurate and avoids implying any dosing guidance at all.
Why grade the evidence for each tract separately?
Because the four links rest on very different foundations. Prolactin elevation from D2 blockade is directly measurable in people; worsened apathy through mesocortical blockade is largely inferred. Grading each row lets a reader see that difference, and graders in this course typically read for exactly that distinction between measured and inferred.
Where can I find a free NU670 Unit 6 sample paper?
The complete NU670 Unit 6 dopamine pathway analysis is on this page, covering all four tracts with graded evidence, the patient explanation and three practical changes to his care, plus four references. An analysis for a different drug or case can be requested.
What occupancy thresholds are used in NU670 Unit 6?
From the Kapur PET study of first-episode patients on haloperidol: clinical response became likely above about 65 percent D2 occupancy, raised prolactin above about 72 percent and extrapyramidal effects above about 78 percent.